IGHA1 and Hematuria: These results further substantiate the notion that hematuria improvement necessitates a prolonged period.The novel oral targeted-release budesonide formulation, Nefecon, effectively inhibits the formation of Gd-IgA1 and has demonstrated a significant improvement in hematuria in a recent study [27].